Bevacizumab, a humanised monoclonal antibody directed against VEGF, was the first antiangiogenic agent to be licensed in the treatment of cancer and has improved survival when administered in combination with chemotherapy in a broad range of epithelial malignancies (Hurwitz et al, 2004; Sandler et al, 2006; Miller et al, 2007). This evidence concerns the gene VEGFA and cancer.